Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995. Wikipedia.


Time filter

Source Type

The present invention provides a crystal comprising the L-malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, wherein the crystal has characteristic diffraction peaks at 13.2 and 24.2 degrees two-theta in a powder X-ray diffraction pattern, for use as a medicament.


— Rising prevalence of chronic diseases associated with thrombotic disease require long-term administration of antithrombotic drugs, which is the key factor enhancing the demand for antithrombotic drugs market. Furthermore, growing geriatric population, increasing hereditary diseases, lack of physical activity, increasing awareness among patients about life-threatening diseases, changing lifestyles and increasing hypertension are the factors favouring market growth. However, off- patented drugs, postoperative bleeding and availability of generic antithrombotic drugs would restrict the antithrombotic drugs market growth. Furthermore, new product launches by key vendors, up-gradation in the antithrombotic drugs and recent R&D programs by major players to develop new drugs are the key opportunities for the market. Asia Pacific is expected to grasp major revenue and volume share in antithrombotic drugs market and is expected to grow with a high CAGR during the forecast period. This growth is attributed to increasing patient population in China and India. North America and Europe regions have significant penetration of antithrombotic drugs due to continual R&D activities for new drug development and high prevalence rate of cardiac and cancer diseases. Some of the key global players in antithrombotic drugs market are Bayer AG, Johnson & Johnson Services Inc., Sanofi, Boehringer Ingelheim GmbH, Pfizer Inc., Abbott laboratories, Dr. Reddy’s Laboratories, Pharmacia Inc., Eli Lilly and Company, The Medicines Company, Genentech Inc., Bristol-Myers Squibb., Watson laboratories inc, Zydus pharmaceuticals Inc. and Otsuka. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com


The invention relates to a solid pharmaceutical composition comprising cytisine as an active substance. The composition is characterized by that it contains from 20% to 75% by weight of microcrystalline cellulose, glidant and at least one pharmaceutically acceptable excipient chosen from a group comprising: mannitol, colloidal silicon dioxide, calcium hydrogen phosphate, whereby at least 60% of cytisine particles have size from 10 m to 200 m.


Patent
Pharmacia | Date: 2011-03-02

An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipients, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.


Patent
Pharmacia | Date: 2013-07-31

The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.


Patent
Pharmacia | Date: 2011-02-09

Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.


Patent
Pharmacia | Date: 2014-01-28

An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.


Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms.


Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms.


The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

Loading Pharmacia collaborators
Loading Pharmacia collaborators